COPENHAGEN, Denmark & ST. LOUIS--(BUSINESS WIRE)--As part of their commitment to develop and commercialize innovative microbial solutions for farmers through The BioAg Alliance, Monsanto Company and Novozymes today shared details of their newest product, the corn inoculant Acceleron® B-300 SAT. Derived from a fungus found in soil, Acceleron B-300 SAT showed a two-year average yield advantage of more than 3 bushels per acre. The Acceleron B-300 SAT inoculant will be applied to all of Monsanto’s new 2017 corn hybrids sold in the United States.
“Harnessing the power of nature’s microbes, farmers will be able to produce more crops while using fertilizer more efficiently and producing less CO2. This will benefit agriculture, consumers and the environment,” said Colin Bletsky, Novozymes’ Vice President for BioAg. “This is the first product jointly developed by Monsanto and Novozymes, and it shows the kind of innovation we can achieve in The BioAg Alliance. We believe it could be applied to more than 90 million acres by 2025 and become one of the biggest biological products in the ag industry.”
Farmers use seed coatings to protect their crops from yield-robbing threats, to improve plant health, and to increase nutrient availability. Acceleron B-300 SAT increases plants’ ability to take up nutrients and is an improved formulation of the JumpStart® inoculant (Penicillium bilaiae), a product that existed in Novozymes' pipeline before the formation of The BioAg Alliance.
The spores in previous versions of JumpStart last about 120 days on the seed after application. This means that farmers using JumpStart inoculants must treat their seeds within a short time before planting. With Acceleron B-300 SAT inoculant, scientists from Monsanto and Novozymes have developed a formulation that, when seed is stored in proper conditions, is viable for at least two years on the seed and is generally compatible with other seed coating chemistries. This allows Monsanto to coat the seeds with the microbial product before the seeds are shipped to retailers and farmers. Acceleron B-300 SAT inoculant is the first ‘upstream’ corn inoculant ever developed.
“Seed applied products – whether microbial or chemistry-based – can and should work together to help growers protect their seed investment and get more out of every acre,” said Juan Ferreira, Global Vice President of Monsanto’s Vegetable Seeds, Seed Applied Solutions and Crop Protection businesses. “Combining the fermentation and formulation expertise of Novozymes’ scientists – along with the innovative approach to seed coating and field-testing capabilities of the Monsanto team – produced a product that will give growers more flexibility in their application decisions and can ultimately result in higher yield.”
The Acceleron® B-300 SAT inoculant will be added to Monsanto’s Seed Applied Solutions portfolio. In addition to applying the product to its DEKALB®, Channel® and regional brands’ new 2017 corn hybrids, Monsanto said it will offer the product to its licensees and distributors.
Further highlights of The BioAg Alliance’s 2016 microbial discovery field trial results – along with 2017 field trial plans – will be announced as part of Monsanto’s First Quarter FY2016 Earnings Conference Call and R&D Pipeline Update on Jan. 5, 2017.
About The BioAg Alliance
First announced in December 2013, The BioAg Alliance is unique in the industry, bringing together Novozymes’ BioAg operations and capabilities within microbial discovery, development and production with Monsanto’s microbial discovery, advanced biology, field testing and commercial capabilities. The result is a comprehensive discovery, development and commercial collaboration to help farmers globally meet the challenge of producing more with less in a sustainable way – for the benefit of agriculture, consumers, the environment and society at large.
About Novozymes
Novozymes is the world leader in biological solutions. Together with customers, partners and the global community, we improve industrial performance while preserving the planet’s resources and helping build better lives. As the world’s largest provider of enzyme and microbial technologies, our bioinnovation enables higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel and many other benefits that we rely on today and in the future. We call it Rethink Tomorrow. www.novozymes.com
About Monsanto
Monsanto is committed to bringing a broad range of solutions to help nourish our growing world. We produce seeds for fruits, vegetables and key crops – such as corn, soybeans, and cotton – that help farmers have better harvests while using water and other important resources more efficiently. We work to find sustainable solutions for soil health, help farmers use data to improve farming practices and conserve natural resources, and provide crop protection products to minimize damage from pests and disease. Through programs and partnerships, we collaborate with farmers, researchers, nonprofit organizations, universities and others to help tackle some of the world’s biggest challenges. To learn more about Monsanto, our commitments and our more than 20,000 dedicated employees, please visit: discover.monsanto.com and monsanto.com. Follow our business on Twitter® at twitter.com/MonsantoCo, on the company blog, Beyond the Rows® at monsantoblog.com or subscribe to our News Release RSS Feed.
Monsanto Cautionary Statements Regarding Forward-Looking Information:
Certain statements contained in this release are “forward-looking statements,” such as statements concerning the company’s anticipated financial results, current and future product performance, regulatory approvals, business and financial plans and other non-historical facts, as well as the proposed transaction with Bayer Aktiengesellschaft (“Bayer”). These statements are based on current expectations and currently available information. However, since these statements are based on factors that involve risks and uncertainties, the company’s actual performance and results may differ materially from those described or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, among others: risks related to the proposed transaction between the company and Bayer, including the risk that the company’s shareowners do not approve the transaction, the risk that the regulatory approvals required for the transaction may not be obtained on the anticipated terms or time frame or at all, the risk that the other conditions to the completion of the transaction may not be satisfied, the risk that disruptions or uncertainties related to the proposed transaction could adversely affect the company’s business, financial performance and/or relationships with third parties, and the risk that certain contractual restrictions during the pendency of the transaction could adversely affect the company’s ability to pursue business opportunities or strategic transactions; continued competition in seeds, traits and agricultural chemicals; the company’s exposure to various contingencies, including those related to intellectual property protection, regulatory compliance and the speed with which approvals are received, and public understanding and acceptance of our biotechnology and other agricultural products; the success of the company’s research and development activities; the outcomes of major lawsuits, including potential litigation related to the proposed transaction with Bayer; developments related to foreign currencies and economies; fluctuations in commodity prices; compliance with regulations affecting our manufacturing; the accuracy of the company’s estimates related to distribution inventory levels; the recent increases in levels of indebtedness, continued availability of capital and financing and rating agency actions; the company’s ability to fund its short-term financing needs and to obtain payment for the products that it sells; the effect of weather conditions, natural disasters, accidents, and security breaches, including cybersecurity incidents, on the agriculture business or the company’s facilities; and other risks and factors detailed in the company’s most recent periodic report to the SEC. Undue reliance should not be placed on these forward-looking statements, which are current only as of the date of this release. The company disclaims any current intention or obligation to update any forward-looking statements or any of the factors that may affect actual results.
ALWAYS READ AND FOLLOW PESTICIDE LABEL DIRECTIONS. Acceleron®, DEKALB® and JumpStart® are registered trademarks of Monsanto Technology LLC. Channel® is a registered trademark of Channel Bio, LLC. ©2016 Monsanto Company.
